CJC-1295 No DAC / Modified GRF (1-29)

CJC-1295 No DAC is a synthetic research peptide related to GHRH (Growth Hormone-Releasing Hormone). In the research-peptide market, the term “CJC-1295 No DAC” is commonly used to refer to Modified GRF (1-29), a short-acting GHRH analog.

Unlike CJC-1295 with DAC, this version does not incorporate a Drug Affinity Complex (DAC) modification and therefore lacks the albumin-binding design responsible for the prolonged pharmacokinetic profile of the DAC-containing form. This makes it relevant to research involving shorter-duration and pulsatile GHRH/GH signaling.

In endocrine research, CJC-1295 No DAC is investigated in connection with GHRH receptor activation, pituitary GH release, pulsatile growth hormone signaling, the GH/IGF-1 axis, and associated endocrine and metabolic regulatory mechanisms.

It can also serve as an experimental tool for comparing short-acting GHRH analogs with DAC-containing long-acting analogs in terms of receptor signaling, duration of activity, and endocrine responses.

CJC-1295 No DAC / Modified GRF (1-29) remains a research compound and should not be represented as having established muscle-building, fat-loss, anti-aging, or performance-enhancing effects in humans.

Livraison standard offerte dès 50 $ vers les États-Unis, le Canada, le Mexique et l'Europe. Expédition sous 1 jour ouvré.

Pas convaincu ? Renvoyez le produit sous 30 jours pour un remboursement intégral, même ouvert.